Phase 2 Hepatitis B Trial, Recruiting (NCT07179575)

Phase 2 Hepatitis B Trial, Recruiting NCT07179575 Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. Condition: Hepatitis B

Printed from Voxsanity (voxsanity.com.au) — NCT07179575 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis B

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part 1 (people not currently on treatment): People with hepatitis B who have never been treated or are not currently being treated, where their hepatitis B virus levels in the blood and a protein produced by the virus (called HBsAg) both fall within specific ranges set by the trial (confirm exact values with trial site)
Part 2 (people currently on treatment): People with hepatitis B whose virus levels in the blood are very low or undetectable, and whose HBsAg levels fall within a specific range set by the trial (confirm exact values with trial site)

Who may not be able to join:

People who also have an infection with hepatitis A, C, D, or E virus, or HIV, or who have another significant liver condition not caused by hepatitis B
People who have a history of, or currently have, cirrhosis (scarring of the liver)
People whose liver enzyme or liver function blood test results — including ALT, AST, bilirubin, or INR — fall outside the acceptable ranges set by the trial, which may suggest the liver is under significant stress (confirm exact values with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07179575

Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.

Phase: Phase 2

Status: Recruiting

Condition: Hepatitis B

More information: https://clinicaltrials.gov/study/NCT07179575

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Part 1 (people not currently on treatment): People with hepatitis B who have never been treated or are not currently being treated, where their hepatitis B virus levels in the blood and a protein produced by the virus (called HBsAg) both fall within specific ranges set by the trial (confirm exact values with trial site)
Part 2 (people currently on treatment): People with hepatitis B whose virus levels in the blood are very low or undetectable, and whose HBsAg levels fall within a specific range set by the trial (confirm exact values with trial site)

Who may not be able to join:

People who also have an infection with hepatitis A, C, D, or E virus, or HIV, or who have another significant liver condition not caused by hepatitis B
People who have a history of, or currently have, cirrhosis (scarring of the liver)
People whose liver enzyme or liver function blood test results — including ALT, AST, bilirubin, or INR — fall outside the acceptable ranges set by the trial, which may suggest the liver is under significant stress (confirm exact values with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Shanghai Longwood Biopharmaceuticals Co., Ltd.

Registry

ClinicalTrials.gov

Start date

1 October 2025

Est. completion

1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline in HBV DNA Viral Load Assay

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov